A Multi-center, Randomized, Double-Blind, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety, Efficacy and Pharmacokinetics of DFD-25 (Zileuton Ointment), 1.25% and 5%, in Subjects with Moderate to Severe Atopic Dermatitis (AD) Over a 4 Week Treatment Period

Start Date02 Dec 2019

Sponsor / Collaborator-

NCT03571620

/ CompletedPhase 2

A Multicenter, Randomized, Phase 2, Double-blind, Vehicle-controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of Q301 Cream in Adolescents and Adults With Mild to Moderate Atopic Dermatitis

This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects with mild to moderate AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day for 8 consecutive weeks.

Start Date21 Jun 2018

Sponsor / Collaborator

Qurient Co., Ltd.

NCT02348203

/ CompletedPhase 2IIT

Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers

This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.

Start Date13 Jan 2016

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Zileuton

100 Translational Medicine associated with Zileuton

100 Patents (Medical) associated with Zileuton

667

Literatures (Medical) associated with Zileuton

31 Dec 2025·REDOX REPORT

Synergistic effects of AgNPs and zileuton on PCOS via ferroptosis and inflammation mitigation

Article

Author: Shatat, Doaa ; Atef, Marwa Mohamed ; Awad, Marwa Mahmoud ; Ibrahim, Rowida Raafat ; Farghal, Eman E. ; Motawea, Shaimaa M. ; El hanafy, Hend Ahmed ; Elesawy, Rasha ; Eltokhy, Amira K. ; El-Deeb, Omnia Safwat ; El-shaer, Rehab Ahmed Ahmed ; Ismail, Radwa ; Hafez, Yasser Mostafa

BACKGROUND:

The most prevalent endocrine disorder affecting women is PCOS. Programmed death of ovarian cells has yet to be elucidated. Ferroptosis is a kind of iron-dependent necrosis featured by significantly Fe⁺²-dependent lipid peroxidation. The ongoing study aimed to reinforce fertility by combining therapy with AgNPs and (Zileuton) in PCOS rats' model.

METHODS:

The study included 75 adult female rats divided into 5 groups; control, PCOS, PCOS treated with AgNPs, PCOS treated with Zileuton, and PCOS group treated with AgNPs and Zileuton. The study investigated the anti-ferroptotic, anti-inflammatory, antioxidant, antiapoptotic, histopathological and immunohistochemical examinations of COX-2 and VEGF.

RESULTS:

The combination of AgNPs and Zileuton showed significant reduction of inflammatory mediators (IL-6, TNF-α, NFk-B) compared with diseased group (P-value < 0.05), regression of ferroptosis marks (Panx1 and TLR4 expression, Fe⁺² levels) compared with diseased group (P-value < 0.05), depression of apoptotic marker caspase 3 level compared with diseased animals (P-value < 0.05), depression of MDA level, elevation of HO-1, GPx4 activity, and reduction of Cox2 and VEGF as compared with the diseased, AgNPs or zileuton-treated groups (P-value < 0.05).

CONCLUSION:

The study showed that the combination of AgNPs and zileuton guards against, inflammation, apoptosis, and ferroptosis in PCO.

01 Mar 2025·BIOORGANIC CHEMISTRY

Exploration of anti-inflammatory activity of pyrazolo[3,4-d]pyrimidine/1,2,4-oxadiazole hybrids as COX-2, 5-LOX and NO release inhibitors: Design, synthesis, in silico and in vivo studies

Article

Author: Ibrahim, Tarek S ; Salem, Ibrahim M ; Al-Awadh, Mohammed A ; Allam, Rasha M ; Alharbi, Abdulrahman S ; Aziz, Marwa A ; Ahmed, Osama A A ; Elsayed Abouzed, Deiaa E ; Abuo-Rahma, Gamal El-Din A ; Mohamed, Mamdouh F A

New pyrazolo[3,4-d]pyrimidine derivatives 7a-h and 8a-h were synthesized and evaluated for their in vitro inhibitory potential against COX-1, COX-2, 5-LOX along with the NO release inhibitory activity to assess their anti-inflammatory potential. Most compounds confered inhibitory activity at a micromolar level and exhibited prominent selectivity towards COX-2 especially in the 8a-h series. The most useful compound 8e as a COX-2/5-LOX dual inhibitor, exhibited IC₅₀ results of; 1.837 µM for COX-2, 2.662 µM for 5-LOX with an acceptable NO release inhibition rate of 66.02 %. Compounds 7e, 7f, 8e and 8f proved their efficiency as 5-LOX/NO release dual inhibitors; with IC₅₀ values of 2.833, 1.952, 2.662 and 1.573 µM, respectively for 5-LOX biotarget, and with superior NO inhibitory ratio of 73.85, 65.57, 66.02 and 72.28 %, respectively. The in vivo anti-inflammatory assay explored that 7e is the most effective with minimal gastric ulceration prevalence. Molecular docking in the active site of both COX-2 and 5-LOX showed that, the most active 8e and 7e are correctly oriented inside the COX-2 binding pocket with unique binding mode independently on the reference celecoxib. Also, they demonstrated superior binding affinities to the 5-LOX enzyme over both the Zileuton as a reference drug and the normal ligand 30Z. The stability of the complex formed between the most promising candidates 7e or 8e with the COX-2 and 5-LOX active sites, was considered using a typical atomistic 100 ns dynamic simulation study. Investigation of the SAR revealed the importance of both the sulfonamide group in the 8a-h series and the substituents of the 3-phenyl ring tethered on the 1,2,4-oxadiazole core.

01 Jan 2025·ARCHIV DER PHARMAZIE

Seasonal metabolic variation in the essential oil composition of various Tabebuia species and evaluation of their anti‐inflammatory activity in vitro and in silico

Article

Author: El‐Ahmady, Sherweit H. ; Khaled, Nesma ; Youssef, Fadia S. ; Ibrahim, Nehal

Abstract:

The seasonal variation in essential oil from four Tabebuia species, T. impetiginosa, T. rosea, T. argentea, and T. guayacan, was explored using gas chromatography–mass spectrometry analysis. A total of 90 components were tentatively identified. Among the four Tabebuia species, the most predominant components in spring were phytol (67.5%), limonene (50.1%), (Z,Z,Z)‐7,10,13‐hexadecatrienal (67.5%), and 1‐octen‐3‐ol (80.4%), respectively. Chemometric discrimination of the four Tabebuia species was performed employing principal component analysis, which classified the samples into three main clusters while the rest of the samples were scattered in the whole plot. The season of collection impact on essential oils composition and yield was illustrated. 5‐Lipooxygenase inhibitory effect of spring season essential oils was assessed, showing that all essential oils exhibited certain inhibition, where T. rosea showed the most potent effect, exhibiting an IC50 value of 1.8 μg/mL, compared to the standard zileuton (0.68 μg/mL). Moreover, an in silico molecular docking study was performed for the predominant metabolites against the 5‐LOX active pocket. Among all the docked compounds, eicosane showed the best fitting score, then norphytane, with ∆G of −38.39 and −29.77 kcal/mol, respectively. Thus, Tabebuia species could offer a natural and relatively safe anti‐inflammatory candidate that requires further clinical trials to be supported.

News (Medical) associated with Zileuton

19 Sep 2023

·synapse.patsnap.com

Targeting 5-lipoxygenase - Leukotriene inhibitor

Leukotrienes are a group of inflammatory mediators produced by the metabolism of arachidonic acid (AA) through the 5-lipoxygenase (5-LO) pathway, featuring a conjugated triene structure of a 20-carbon unsaturated acid. They are classified into six types - A, B, C, D, E, F, based on their substituents. Among these, LTC4, LTD4, and LTE4 all contain cysteinyl at C-6, collectively referred to as cysteinyl leukotrienes (CysLTs). Leukotrienes can be produced by cells after various immunological or non-immunological stimuli, through autocrine or paracrine mechanisms. These stimuli include antigens, immune complexes, complements, cytokines, osmotic pressure, and environmental pollutants. Once leukotrienes bind with specific G-protein coupled receptors (GPCRs) on the cell surface, they activate Gq proteins leading to an increase in intracellular calcium concentrations, and activating Gi proteins causing a decrease in cAMP, both of which can trigger a cascade of kinase protein signal transduction, inducing intracellular transcription responses and cell movement, thereby widely participating in the body's immune response. Currently, anti-leukotriene drugs are primarily divided into two categories: the first are leukotriene receptor antagonists, which inhibit tissue responses to leukotrienes by blocking leukotriene receptors, including Montelukast, Zafirlukast, and Pranlukast; the second one are leukotriene synthesis inhibitors, which inhibit the activity of the key enzyme 5-LO in the leukotriene synthesis pathway, thereby inhibiting the synthesis of cysteinyl leukotrienes and LTB4. Leukotriene Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 18 Sep 2023, there are a total of 142 5-LOX drugs worldwide, from 105 organizations, covering 60 indications, and conducting 52 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. 5-LOX, or 5-lipoxygenase, is an enzyme that plays a crucial role in the human body's inflammatory response. It is responsible for the conversion of arachidonic acid into leukotrienes, which are potent mediators of inflammation. These leukotrienes are involved in various physiological processes, including immune response, allergic reactions, and the development of certain diseases such as asthma and arthritis. Due to its involvement in inflammation, 5-LOX has become an attractive target for pharmaceutical research, with the aim of developing drugs that can modulate its activity and potentially alleviate inflammatory conditions. Drugs under this target have been approved for indications such as asthma. Small molecule drugs are progressing most rapidly, with one approved and six in preclinical development. The United States is the leading country in terms of drug development for target 5-LOX, followed by Australia, Israel, and the European Union. China has made progress in preclinical development for this target. The current competitive landscape for target 5-LOX is characterized by a diverse range of companies and drug types. The presence of biosimilars indicates intense competition around the innovative drugs. Further research and development are needed to explore the potential of target 5-LOX in various indications and to expand its market presence globally. Leukotriene Pathway Inhibitor: ZileutonZileuton is a Leukotriene pathway inhibitor, classified as a 5-lipoxygenase inhibitor, used for the treatment of asthma and allergic rhinitis. Zileuton is associated with rare drug-induced liver disease and is considered contraindicated in patients with active liver disease. The 5- lipoxygenase is responsible for the conversion of arachidonic acid into leukotriene A4, leukotriene A4 is an effective mediator of the inflammatory cascade reaction, playing a pivotal role in asthma and allergic rhinitis. Zileuton has been shown to improve the symptoms of asthma and allergic rhinitis and was approved for use in the United States in 1996. Current indications include the prophylaxis and chronic treatment of asthma in adults and children aged 12 and above. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Given its approval for asthma, Zileuton is expected to have a positive impact on patients suffering from this condition. By targeting 5-LOX, the drug helps to reduce the production of leukotrienes, which are known to contribute to airway inflammation and bronchoconstriction in asthma patients. By inhibiting this pathway, Zileuton can potentially alleviate symptoms and improve lung function in individuals with asthma. In summary, Zileuton is a small molecule drug developed by Abbott Laboratories that targets 5-LOX and is indicated for the treatment of asthma. Its approval in 1996 in the United States signifies its efficacy and safety in managing this respiratory condition. As a therapeutic option, Zileuton has the potential to provide relief to asthma patients by reducing airway inflammation and constriction. Targeted 5-LOX Small Molecule Drugs:A-72694The drug A-72694 is a small molecule drug that targets 5-LOX, which stands for 5-lipoxygenase. It is primarily developed for the treatment of asthma, a respiratory disease that affects the immune system. The drug is currently in the preclinical phase, indicating that it is still undergoing laboratory testing and has not yet progressed to human clinical trials. A-72694 is being developed by Abbott Laboratories, a well-known pharmaceutical company with expertise in the field of biomedicine. The therapeutic areas of A-72694 include immune system diseases and respiratory diseases, with asthma being the active indication. This indicates that the drug is specifically designed to target and treat asthma, a chronic condition characterized by inflammation and narrowing of the airways. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. As a small molecule drug, A-72694 is likely to have a low molecular weight and can be easily synthesized in a laboratory setting. Small molecule drugs are typically orally administered and can easily penetrate cell membranes, allowing them to interact with specific targets within the body. Although the drug is still in the preclinical phase, it shows promise for the treatment of asthma by targeting 5-LOX. 5-LOX is an enzyme involved in the production of leukotrienes, which are inflammatory molecules that play a role in asthma pathogenesis. By inhibiting 5-LOX, A-72694 may help reduce inflammation and improve respiratory symptoms in asthma patients. In summary, A-72694 is a small molecule drug developed by Abbott Laboratories that targets 5-LOX for the treatment of asthma. It is currently in the preclinical phase, and further research and development are needed to determine its safety and efficacy in human clinical trials.

12 May 2023

·www.drugs.com

Get Relief With the Most Common Asthma Medications

FRIDAY, May 12, 2023 -- Receiving a diagnosis of asthma may be frightening, but learning what the treatment options are can help alleviate the anxiety that comes with diagnosis. Depending on the severity, certain asthma medications may help you manage your symptoms. Here, experts break down the most common long-term and quick-acting medications for asthma, how they work and potential side effects. Long-term medications These drugs are ones the patient takes daily as a means of controlling asthma and preventing asthma attacks. These can be in pill form or used as inhalers. Bronchodilators: Long-acting beta-2 agonists (LABA) relax the muscle bands around your airway (bronchi), making it easier to get air in and mucus out. These medications for asthma are taken twice a day through an inhaler and last up to 12 hours, according to the Cleveland Clinic . LABA medications should be given with a corticosteroid. (See combination medications below.) The main side effects of LABA medications are nervous or shaky feelings, hyperactivity, overexcitement, increased heart rate, upset stomach and trouble sleeping. Salmeterol (Serevent) Formoterol (Foradil) Long-acting muscarinic antagonists (LAMA) also relax the muscle bands around your airway, the National Heart, Lung, and Blood Institute (NHLBI) says. This asthma medication is used if the steroid/LABA combination doesn’t give enough relief. Do not use this medication if you have glaucoma or are at risk of urinary retention. Tiotropium bromide (Respimat) Theophylline. While not used often, theophylline can be useful in relaxing the airways and preventing reactions to irritants. It is taken as a pill and used for mild asthma symptoms. You may need to have blood tests drawn on a regular basis to make sure the level of medication is correct, the Mayo Clinic says. Side effects are the same as the other bronchodilators, but may also include chest pain or discomfort, dizziness, fainting, increase in urine volume or seizures. Theophylline (Theo-24, Theo-Dur, Slo-Bid, and others) Corticosteroids: Corticosteroids are steroids that reduce inflammation in the airways, according to the NHLBI. They may be taken as a pill, although very few patients are on the pill for long term. It is frequently used in an inhaler, often combined with a LABA. Side effects from the inhaled form are thrush (a mouth infection) and a hoarse voice. Inhaled corticosteroids include: Fluticasone (Flovent HFA, Arnuity Ellipta, others) Budesonide (Pulmicort Flexhaler) Mometasone (Asmanex Twisthaler) Beclomethasone (Qvar RediHaler) Ciclesonide (Alvesco) Combination asthma medications (Corticosteroid and LABA): Fluticasone and salmeterol (Advair) Budesonide and formoterol (Symbicort) Fluticasone and Vilanterol (Breo) Leukotriene modifiers reduce swelling and help keep your airways open for up to 24 hours. According to Mayo Clinic, these medications block the effects of leukotrienes, immune system chemicals that cause asthma symptoms. Side effects are uncommon, but may include nausea, headache, tiredness or diarrhea. Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Quick-acting asthma medications These are a group of medications that are used when a patient has a flare-up or an asthma attack. Inhaled short-acting beta2-agonists (SABAs) open the airways so air can flow through them during an asthma attack. They start working within 15 to 20 minutes and continue to work for 4 to 6 hours, according to the Cleveland Clinic. Side effects can include tremors, rapid heartbeat, allergic reactions, muscle pain, worsening breathing, dry mouth, headache, sore throat or trouble sleeping. Inhaled forms of SABA medications include: Albuterol (Ventolin) Levalbuterol (Xopenex) Albuterol and ipratropium bromide combination (DuoNeb) Corticosteroids. Oral corticosteroids are usually prescribed for short-term use to help a patient overcome a flare-up. This type of medication quickly reduces swelling and inflammation in the airways. Side effects include: Cataracts, osteoporosis, weight gain, high blood sugar, increased risk of infections, thinning bones and fractures, thin skin, bruising and slower wound healing, mood swings, depression and aggressive behavior. Prednisone (Deltasone, Prednicot, and others ) Methylprednisolone (Medrol, Solu-Medrol, Depo-Medrol) Short-acting anticholinergic bronchodilators help open the airways quickly. This medicine may be less effective than SABAs, but it is an option for people who experience side effects with other medications, the Cleveland Clinic says. Side effects you may experience with these inhalers are dry throat, eyes and nose; unusual taste; nausea and vomiting; or temporary blurred vision if the medicine gets in your eyes. Ipratropium bromide (Atrovent) Tiotropium bromide (Spiriva Respimat) Corticosteroid reliever. In January 2023, the FDA approved Airsupra, which can be used as needed to prevent bronchoconstriction and asthma attacks. In a study conducted before the approval, the risk of severe asthma exacerbation was significantly lower with a fixed-dose combination of albuterol and budesonide than with as-needed use of albuterol alone. Most common side effects are headache, oral yeast infection, cough, and difficulty speaking. Airsupra (albuterol-budesonide) Posted May 2023

Drug Approval

11 May 2023

·www.drugs.com

The Most Common Allergy Medicines

THURSDAY, May 11, 2023 -- If you suffer from allergies, you know how bothersome and uncomfortable the sneezing and itchy eyes can be. These symptoms are more than irritating — they impact day-to-day activities like work, school, sports, sleeping and even eating. Not only that, but allergies can also cause more serious health problems such as asthma and even anaphylaxis, a life-threatening allergic reaction. Allergies are a common health condition affecting almost one-third of adults in the United States and just over one-quarter of children under 17, according to the U.S. Centers for Disease Control and Prevention . But there is relief at hand: Here’s what you need to know about the most common allergy medicines, the type of allergies they treat, how they work and common side effects. Antihistamines This type of allergy medicine is very effective in relieving allergy symptoms. Mayo Clinic explains this drug type works by blocking histamine, “a symptom-causing chemical released by your immune system during an allergic reaction.” Antihistamines are available as an over-the-counter medication or as a prescription allergy medicine, and they are sold in oral form, as a nasal spray or as eyedrops. This allergy medicine treats symptoms of indoor and seasonal allergies. Common side effects of antihistamines include drowsiness, dry mouth, dizziness, blurred or double vision, mucous thickening and low blood pressure. Common antihistamines include: Oral Loratadine (Alavert, Claritin) Cetirizine (Zyrtec) Diphenhydramine (Benadryl) Doxylamine (Vicks NyQuil, Tylenol Cold and Cough Nighttime) Fexofenadine (Allegra) Nasal spray Olopatadine (Patanase) Eyedrops Ketotifen (Zaditor) Leukotriene modifiers Leukotriene modifiers prevent or lessen the symptoms of allergic rhinitis (hay fever) and allergic asthma. The Cleveland Clinic explains that leukotrienes are chemicals released in the body when you come in contact with an allergen. This causes symptoms like a runny nose and coughing. Leukotriene inhibitors block the effects leukotrienes have on the body or “stop your body from producing them.” This allergy medicine treats symptoms of indoor and seasonal allergies. Leukotriene inhibitors can cause side effects such as cold or flu symptoms, headache, diarrhea, fatigue and itchy skin or rash. More serious side effects like depression, thoughts of suicide, hives, trouble breathing, vomiting and yellowing of the skin or eyes can occur. You should seek medical treatment in these cases. Common leukotriene inhibitors include: Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Corticosteroids Corticosteroids treat mild to severe allergy symptoms by reducing inflammation caused by your body’s reaction to an allergen. Corticosteroids are available in several forms including pills and liquids, nasal sprays, inhalers, creams and eyedrops. They treat allergic inflammation caused by indoor and seasonal allergens as well as insect stings. Severe allergic reactions are treated with oral corticosteroids, according to the Mayo Clinic. Side effects vary depending on the medication form, but can include increased blood glucose levels, high blood pressure, nosebleeds, mouth and throat irritation, and skin irritation. Common corticosteroids by form include: Pills and liquids Prednisolone (Prelone) Methylprednisolone (Medrol) Nasal sprays Budesonide (Rhinocort) Mometasone (Nasonex) Inhalers Fluticasone (Flovent) Mometasone (Asmanex Twisthaler) Creams Betamethasone (Dermabet, Diprolene) Desonide (Desonate, DesOwen) Eyedrops Fluorometholone (Flarex, FML) Loteprednol (Alrex, Lotemax) Immunotherapy Immunotherapy works by modifying the immune system and its reaction to allergens. It’s not used for immediate allergy symptom relief but is a long-term allergy treatment. Immunotherapy treatments (or allergy shots) are prescription medicines. "Allergy shots can be helpful for patients with seasonal and year-round allergies," Miranda Curtiss , an assistant professor at the University of Alabama at Birmingham School of Medicine, said in a recent article . "However, these are a long-term investment that require planning to continue therapy for three to five years for maximal benefit. Asthmatics who want to start allergy shots need to have their asthma under good control first before starting shots." With allergy shots, you are exposed to an allergen over and over until your immune system becomes desensitized and no longer reacts to the allergen, the Mayo Clinic says. This type of treatment is commonly given as allergy shots (subcutaneous immunotherapy, or SCIT), but is also available in a form given under the tongue (sublingual immunotherapy, or SLIT). With SCIT, injections are given in your doctor’s office where they can monitor for adverse reactions. Treatment starts with the “build-up phase,” which is once or twice a week, and decreases to a maintenance dose which is once every two to four weeks. Sublingual immunotherapy treatment, like subcutaneous immunotherapy, also exposes you to allergens over a period of time, with the goal of building immunity to the allergen. SLIT tablets are available by prescription and taken daily. Immunotherapy is used to treat seasonal and indoor allergies, as well as insect stings. Side effects include watery eyes, sneezing, mild asthma symptoms, a rash at the injection site, tiredness and headaches. In rare cases, life-threatening reactions such as throat swelling and difficulty breathing can occur. Regardless of the type of allergy or your symptoms, there are options for relief. Reach out to your health care provider to learn more about which remedies are best for you. Posted May 2023

Immunotherapy

100 Deals associated with Zileuton

External Link

KEGG	Wiki	ATC	Drug Bank
D00414	Zileuton	R	DB00744

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	United States	Chiesi USA, Inc	09 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mild Atopic Dermatitis	Phase 2	United States	Qurient Co., Ltd.	21 Jun 2018
Moderate Atopic Dermatitis	Phase 2	United States	Qurient Co., Ltd.	01 Apr 2015
Severe Atopic Dermatitis	Phase 2	United States	Qurient Co., Ltd.	01 Apr 2015
Asthma chronic	Phase 2	-	Critical Therapeutics, Inc.	01 Sep 2007
Acne Vulgaris	Phase 2	United States	Critical Therapeutics, Inc.	01 Nov 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02348203 (CTgov)	Phase 2	Carcinogenesis \| Tobacco Use Disorder	63	Laboratory Biomarker Analysis+Aspirin+Zileuton (Arm I (Aspirin, Zileuton))	dqnokdspln(gcsbsxiiwr) = fhexsptegy inmbmpsgxx (ukyzqzwfon, 2.89) View more	-	23 Mar 2020
				Laboratory Biomarker Analysis (Arm II (Double Placebo))	dqnokdspln(gcsbsxiiwr) = yvfqcinlky inmbmpsgxx (ukyzqzwfon, 2.26) View more
NCT01021215 (CTgov)	Phase 1/2	Tobacco Use Disorder	84	laboratory biomarker analysis+Zileuton (Arm I: Zileuton)	pyrdjyvtwd(nkizzqixmc) = mkjvjshpvb qkfslnsjuh (wwcxxfwcyz, madfhbzeag - thglsjgtau) View more	-	02 Apr 2015
				laboratory biomarker analysis+Celecoxib+Zileuton (Arm II: Zileuton and Celecoxib)	pyrdjyvtwd(nkizzqixmc) = bthpxrmjjl qkfslnsjuh (wwcxxfwcyz, tahqgqfpot - izjvezzkhi) View more
NCT01805687 (CTgov)	Phase 4	Asthma chronic	25	Zileuton extended release	fvfvpwpjyk(ytcecsvrdx) = qfmaqmcjyi bvltvewkih (flddwgplmi, 0.706) View more	-	18 Aug 2014
NCT00467831 (CTgov)	Phase 1/2	Hermanski-Pudlak Syndrome \| Pulmonary Fibrosis	3	Pravastatin+N-Acetylcysteine+Losartan+Erythromycin+Zileuton	fcmvuykenz = inqrxiiaxk jfitrjovnz (wmvcfvdkxh, otvavmxrvy - urmhkmwntq) View more	-	02 Aug 2013
NCT00493974 (Pubmed \| COPD)	Phase 3	Pulmonary Disease, Chronic Obstructive	119	Zileuton 600 mg	kdetuecfsy(vnsbafwito) = gazaqjlqlh oxmidupwti (amkaxyfdfx ) View more	Negative	01 Feb 2011
				Placebo	kdetuecfsy(vnsbafwito) = wcdolprmwv oxmidupwti (amkaxyfdfx ) View more
NCT00493974 (LEUKO, CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	119	Zileuton (Zileuton)	kjdoeiuswg(vszundgrts) = bjmqlgmuqk lgdutwcowu (pvsnfocafv, 2.19) View more	-	03 Mar 2010
				Placebo (Placebo)	kjdoeiuswg(vszundgrts) = klnuapaiyh lgdutwcowu (pvsnfocafv, 3.06) View more
NCT00575861 (Pubmed \| Pulm Pharmacol Ther)	Phase 4	Moderate persistent asthma Add-on	22	Fluticasone 250μg/Salmeterol 50μg	ebldhsswpu(kkxxaxragc) = aqblqukfxz ujjxdgrioo (zuvmmrfhaf ) View more	-	01 Dec 2009
				Fluticasone 250μg/Salmeterol 50μg + Zileuton 600mg	ebldhsswpu(kkxxaxragc) = oqsepzricj ujjxdgrioo (zuvmmrfhaf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis